Evaluating Amgen (AMGN): Is Current Valuation Attractive After Recent 1-Month Momentum?

Amgen (AMGN) shares have generally moved sideways over the past month, with investors weighing recent financial performance and sector trends. The stock remains a steady point of interest for those following pharmaceuticals and biotech.

See our latest analysis for Amgen.

Amgen’s recent 1-month share price return of 6.5% signals some renewed momentum after a flat stretch. However, the 1-year total shareholder return remains down by 4.4%. While short-term gains have caught attention, the longer-term performance highlights the ongoing push and pull between upside potential and periodic market caution.

If you’re looking for more opportunities in pharma and biotech, now is the perfect time to explore our handpicked collection with the See the full list for free.

With Amgen’s valuation still below analyst targets and modest revenue growth in recent quarters, the key question lingers: is this a compelling entry point, or are investors already factoring in the next leg of growth?

Most Popular Narrative: 6.4% Undervalued

Compared to Amgen’s recent closing price, the most followed narrative pegs fair value higher, spotlighting a gap that investors are watching closely. The market’s current mood sets the tone for debate over whether there is upside still to be claimed.

Advancements in personalized and targeted therapies, reflected in the robust late-stage pipeline (for example, MariTide for obesity/type 2 diabetes, Repatha and olpasiran for cardiovascular, multiple bispecific T-cell engagers for oncology), position Amgen to launch high-margin, first-in-class products that drive both top-line growth and margin expansion in the coming years.

Read the complete narrative.

Want to know what’s pushing Amgen’s fair value far beyond its last trade? The secret is in bold margin projections and ambitious product launches. Find out which financial levers analysts bet on to set this target.

Result: Fair Value of $311.88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, shifts in drug pricing policy or increased biosimilar competition could quickly challenge Amgen’s momentum and the optimistic growth outlook that analysts have set.

Find out about the key risks to this Amgen narrative.

Build Your Own Amgen Narrative

If you see the numbers differently or want to dig deeper on your own terms, it only takes a few minutes to shape your own view. Do it your way

A great starting point for your Amgen research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Smart Investment Ideas?

Don’t limit yourself. Set your sights on high-potential opportunities that others might miss. Take action now and pursue tailored investment strategies with these handy tools:

• Boost your portfolio’s potential for strong cash flow by checking out these 854 undervalued stocks based on cash flows based on real financial metrics.
• Tap into the unstoppable rise of artificial intelligence with these 26 AI penny stocks poised for breakthroughs and growth in cutting-edge tech sectors.
• Capture reliable income and outperform low-yield alternatives through these 21 dividend stocks with yields > 3% offering attractive yields over 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com